Transcarotid Artery Revascularization (TCAR) in the Frail

Trans-femoral carotid stenting (TFCAS) fell dramatically out of favor with vascular surgeons after the results of the CREST trial showed higher rates of stroke compared to carotid endarterectomy (CEA)1. The emergence of TCAR presented a novel technology to stent carotid lesions in patients not suitable or considered high risk for a CEA. Multiple recent studies evaluating the outcomes of TCAR have been very encouraging 2-4. This has led to a fast and wide adoption of the technique.
Source: Annals of Vascular Surgery - Category: Surgery Authors: Source Type: research